Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00668564
Other study ID # MT2008-02
Secondary ID 0801M25202
Status Terminated
Phase Phase 2
First received April 25, 2008
Last updated December 3, 2017
Start date March 2008
Est. completion date February 2010

Study information

Verified date December 2017
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell transplantation (HCT).


Description:

This has been an ongoing area of interest by our group at the Univ. of Minnesota, but this is a new protocol to take the place of several older protocols. While survival has been very good on the prior protocols over the past decade, incomplete engraftment has remained somewhat problematic. Therefore, we have modified the preparative regimen somewhat to increase engraftment by replacing anti-thymocyte globulin (ATG) with Campath-1H, a drug that is more immune suppressive. In addition, we have modified the supportive care regimen. Based on this, we will monitor levels of an anti-oxidant therapy (N-acetylcysteine) and biomarkers of inflammation and oxidative stress for the families that consent to these research studies.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date February 2010
Est. primary completion date February 2010
Accepts healthy volunteers No
Gender All
Age group N/A to 21 Years
Eligibility Inclusion Criteria:

- Mucopolysaccharidosis (MPS) Disorders:

- MPS IH (Hurler syndrome)

- MPS-VI (Maroteaux-Lamy syndrome)

- MPS VII (Sly syndrome).

- Glycoprotein metabolic disorders:

- Alpha mannosidosis

- Fucosidosis

- Aspartylglucosaminuria

- Sphingolipidoses and Recessive Leukodystrophies: Presymptomatic patients with globoid cell leukodystrophy (GLD, also known as Krabbe disease) and metachromatic leukodystrophy (MLD) will be eligible for treatment on this protocol. White matter disease by magnetic resonance imaging (MRI) alone is not an exclusion if the patient is asymptomatic.

- Peroxisomal Disorders: Presymptomatic patients with inherited peroxisomal disorders associated with of very long chain fatty acids (VLCFA) elevation, identified by family history or laboratory testing (including neonatal screening), are eligible for this protocol. White matter disease by MRI alone is not an exclusion if the patient is asymptomatic.

- Other Inherited Diseases of Metabolism:

- Wolman syndrome (acid lipase deficiency)

- Niemann-Pick B patients (sphingomyelin deficiency)

- Niemann-Pick C subtype 2

- Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program: Priority will be as follows, although in circumstances in which timing is of the essence, cord blood grafts may be chosen over an unrelated graft, despite the priority listed above.

- Multidisciplinary Evaluation: Patients will be eligible for transplantation only after they are seen and evaluated by members of the Inherited Metabolic and Storage Disease Program (IMSD) team, and the team has offered transplantation to the patient/family.

Exclusion Criteria:

- Symptomatic patients with peroxisomal or lysosomal disorders are excluded but may be considered for other treatment protocols.

- Major organ dysfunction. Evidence of major organ impairment, including:

- Cardiac: left ventricular ejection fraction <40%

- Renal: serum creatinine >2.5 x normal for age

- Hepatic: total bilirubin >3 x normal, or Alanine transaminase (ALT) > 3 x normal

- Pulmonary: requirement for continuous oxygen supplementation

- Pregnancy

- Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology

- Patients >21 years of age.

Study Design


Related Conditions & MeSH terms

  • Alpha Mannosidosis
  • alpha-Mannosidosis
  • Aphasia, Primary Progressive
  • Aspartylglucosaminuria
  • Frontotemporal Dementia
  • Fucosidosis
  • Hurler's Syndrome
  • Krabbe Disease
  • Leukodystrophy, Globoid Cell
  • Maroteaux-Lamy Syndrome
  • Metabolism, Inborn Errors
  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis VI
  • Mucopolysaccharidosis VII
  • Niemann-Pick Disease Type B
  • Niemann-Pick Disease, Type C
  • Niemann-Pick Diseases
  • Pick Disease of the Brain
  • Sly Syndrome
  • Sphingolipidoses
  • Syndrome
  • Wolman Disease
  • Wolman's Disease

Intervention

Procedure:
Stem Cell Transplantation
The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
Drug:
Cyclophosphamide
Days before Transplant Drug Frequency 4 Cyclophosphamide Once, given over 2 hours 3 Cyclophosphamide Once, given over 2 hours 2 Cyclophosphamide Once, given over 2 hours 1 Cyclophosphamide Once, given over 2 hours
Campath-1H
Days before Transplant Drug Frequency 12 Campath-1H Once, given over 2 hours 11 Campath-1H Once, given over 2 hours 10 Campath-1H Once, given over 2 hours
Busulfan
Days before Transplant Drug Frequency 9 Busulfan Four times per day 8 Busulfan Four times per day 7 Busulfan Four times per day 6 Busulfan Four times per day

Locations

Country Name City State
United States University of Minnesota, Fairview Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Achieving Engraftment Rate of successful engraftment - patients who achieved and sustained donor engraftment; donor chimerism by day 100 of at least 90% after undergoing hematopoietic stem cell transplantation. Day 100
Secondary Overall Survival Number of patients alive at timepoints. Day 100, 1 Year, 3 Years
See also
  Status Clinical Trial Phase
Completed NCT03759639 - N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT02435030 - A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C N/A
Completed NCT02534844 - VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease Phase 2/Phase 3
Recruiting NCT05588167 - Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Withdrawn NCT03687476 - Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease Phase 2
Enrolling by invitation NCT05368038 - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Completed NCT01899950 - Longitudinal Study of Cognition With Niemann-Pick Disease, Type C N/A
Active, not recruiting NCT05163288 - A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C Phase 3
Active, not recruiting NCT02612129 - Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C Phase 2/Phase 3
Recruiting NCT03471143 - Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Phase 1/Phase 2
Terminated NCT04958642 - Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease Phase 2/Phase 3
Terminated NCT03879655 - Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 Phase 2/Phase 3
Completed NCT00975689 - Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Phase 1/Phase 2
Withdrawn NCT01306604 - Biomarker for Niemann Pick Type C Disease (BioNPC)
Recruiting NCT00344331 - Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Active, not recruiting NCT05758922 - Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease Phase 2
Completed NCT03910621 - Safety and Efficacy of Miglustat in Chinese NPC Patients Phase 4
Available NCT04316637 - Early Access Program With Arimoclomol in US Patients With NPC